164 related articles for article (PubMed ID: 32324516)
21. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
22. Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology.
Stockton SD; Devi LA
Drug Alcohol Depend; 2012 Mar; 121(3):167-72. PubMed ID: 22115888
[TBL] [Abstract][Full Text] [Related]
23. Opioid receptor heteromers in analgesia.
Costantino CM; Gomes I; Stockton SD; Lim MP; Devi LA
Expert Rev Mol Med; 2012 Apr; 14():e9. PubMed ID: 22490239
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pharmacology of δ-Opioid Receptors.
Gendron L; Cahill CM; von Zastrow M; Schiller PW; Pineyro G
Pharmacol Rev; 2016 Jul; 68(3):631-700. PubMed ID: 27343248
[TBL] [Abstract][Full Text] [Related]
25. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
[TBL] [Abstract][Full Text] [Related]
26. A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.
Knapman A; Santiago M; Connor M
Br J Pharmacol; 2015 May; 172(9):2258-72. PubMed ID: 25521224
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
[TBL] [Abstract][Full Text] [Related]
28. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
Ananthan S
AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
[TBL] [Abstract][Full Text] [Related]
29. In vivo trafficking of endogenous opioid receptors.
Wang Y; Van Bockstaele EJ; Liu-Chen LY
Life Sci; 2008 Nov; 83(21-22):693-9. PubMed ID: 18930741
[TBL] [Abstract][Full Text] [Related]
30. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
[TBL] [Abstract][Full Text] [Related]
31. Implications of phosphoinositide 3-kinase in the mu- and delta-opioid receptor-mediated supraspinal antinociception in the mouse.
Narita M; Ohnishi O; Nemoto M; Yajima Y; Suzuki T
Neuroscience; 2002; 113(3):647-52. PubMed ID: 12150784
[TBL] [Abstract][Full Text] [Related]
32. Activation of the Mu-Delta Opioid Receptor Heteromers Blocks Morphine Rewarding Effects.
Requana Aradas A; Djaboub Y; McCort-Tranchepain I; Hajasova Z; Clémenceau L; Canestrelli C; Mann A; Schulz S; Delaval A; Acher F; Massotte D; Noble F; Marie N
Int J Neuropsychopharmacol; 2023 Jul; 26(7):513-521. PubMed ID: 37343217
[TBL] [Abstract][Full Text] [Related]
33. Spinal activation of delta opioid receptors alleviates cancer-related bone pain.
Otis V; Sarret P; Gendron L
Neuroscience; 2011 Jun; 183():221-9. PubMed ID: 21458544
[TBL] [Abstract][Full Text] [Related]
34. Delta opioid receptor expression correlates to skin ageing and melanin expression in Asian women.
Bigliardi PL; Lo S; Bigliardi E; Dancik Y; Leblanc-Noblesse E; Bigliardi-Qi M
Exp Dermatol; 2024 Jun; 33(6):e15096. PubMed ID: 38922774
[TBL] [Abstract][Full Text] [Related]
35. Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance.
Zhang X; Bao L; Guan JS
Trends Pharmacol Sci; 2006 Jun; 27(6):324-9. PubMed ID: 16678916
[TBL] [Abstract][Full Text] [Related]
36. The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling.
Fidilio A; Grasso M; Turnaturi R; Caruso G; Spitale FM; Vicario N; Parenti R; Spoto S; Musso N; Marrazzo A; Chiechio S; Caraci F; Pasquinucci L; Parenti C
Front Pharmacol; 2021; 12():749365. PubMed ID: 34690781
[TBL] [Abstract][Full Text] [Related]
37. Spinal μ and δ opioids inhibit both thermal and mechanical pain in rats.
Normandin A; Luccarini P; Molat JL; Gendron L; Dallel R
J Neurosci; 2013 Jul; 33(28):11703-14. PubMed ID: 23843537
[TBL] [Abstract][Full Text] [Related]
38. Enkephalin analog, cyclo[N(ε),N(β)-carbonyl-D-Lys(2),Dap(5)] enkephalinamide (cUENK6), inhibits the ethanol withdrawal-induced anxiety-like behavior in rats.
Gibula-Bruzda E; Marszalek-Grabska M; Witkowska E; Izdebski J; Kotlinska JH
Alcohol; 2015 May; 49(3):229-36. PubMed ID: 25716198
[TBL] [Abstract][Full Text] [Related]
39. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
40. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
Lei W; Vekariya RH; Ananthan S; Streicher JM
J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
